NCT01815957

Impact of Ranolazine on Coronary Microcirculatory Resistance

Impact of Ranalozine on Coronary Microcirculatory Resistance- A Prospective Single Center Study to Evaluate the Effect of Ranalozine in Microcirculatory Resistance (MICRO Study)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: University of New Mexico · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to determine if Ranolazine treatment improves coronary microcirculation function among patients with coronary microcirculation dysfunction. We are also looking to learn if symptomatic improvement of chest pain during treatment with Ranalozine is related to improved coronary microcirculation function.

Conditions

• Coronary Microcirculation
• Coronary Artery Disease
• Myocardial Disease
• Ischemia

Interventions

Type	Name	Description
DRUG	Rnalozine	. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.

Timeline

• Start date: 2012-05-01
• Primary completion: 2016-03-01
• Completion: 2016-03-01
• First posted: 2013-03-21
• Last updated: 2023-12-26
• Results posted: 2023-12-26

Locations

1 site across 1 country: United States